40.25
0.00
(0.00%)
At close: 1:30:16 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
672,850.00
652,620.00
732,276.00
774,270.00
665,341.00
Cost of Revenue
956,074.00
1,027,811.00
845,948.00
636,661.00
478,809.00
Gross Profit
-283,224.00
-375,191.00
-113,672.00
137,609.00
186,532.00
Operating Expense
211,192.00
228,042.00
300,165.00
230,097.00
140,267.00
Operating Income
-494,416.00
-603,233.00
-413,837.00
-92,488.00
46,265.00
Net Non Operating Interest Income Expense
-17,701.00
-9,585.00
-15,399.00
-2,223.00
616.00
Pretax Income
-527,661.00
-683,981.00
-462,841.00
-87,518.00
27,967.00
Tax Provision
8,673.00
-1,134.00
-9,210.00
2,340.00
-2,981.00
Net Income Common Stockholders
-536,334.00
-682,847.00
-453,631.00
-89,858.00
30,948.00
Diluted NI Available to Com Stockholders
-536,334.00
-682,847.00
-453,631.00
-89,858.00
30,948.00
Basic EPS
-2.60
-3.32
-2.74
-0.61
0.24
Diluted EPS
-2.60
-3.32
-2.74
-0.61
0.24
Basic Average Shares
206,129.70
205,528.00
165,337.00
148,484.00
127,994.00
Diluted Average Shares
206,129.70
205,528.00
165,337.00
148,484.00
128,710.00
Total Expenses
1,167,266.00
1,255,853.00
1,146,113.00
866,758.00
619,076.00
Net Income from Continuing & Discontinued Operation
-536,334.00
-682,847.00
-453,631.00
-89,858.00
30,948.00
Normalized Income
-537,444.40
-683,976.12
-423,093.01
-95,583.60
39,641.60
Interest Income
10,997.00
17,660.00
3,795.00
307.00
1,481.00
Interest Expense
28,698.00
27,245.00
19,194.00
2,530.00
865.00
Net Interest Income
-17,701.00
-9,585.00
-15,399.00
-2,223.00
616.00
EBIT
-498,963.00
-656,736.00
-443,647.00
-84,988.00
28,832.00
EBITDA
-191,558.00
-341,955.00
-161,094.00
82,833.00
166,028.00
Reconciled Cost of Revenue
956,074.00
1,027,811.00
845,948.00
636,661.00
478,809.00
Reconciled Depreciation
307,405.00
314,781.00
282,553.00
167,821.00
137,196.00
Net Income from Continuing Operation Net Minority Interest
-536,334.00
-682,847.00
-453,631.00
-89,858.00
30,948.00
Total Unusual Items Excluding Goodwill
1,388.00
1,131.00
-31,158.00
7,157.00
-10,867.00
Total Unusual Items
1,388.00
1,131.00
-31,158.00
7,157.00
-10,867.00
Normalized EBITDA
-192,946.00
-343,086.00
-129,936.00
75,676.00
176,895.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
277.60
1.88
-620.01
1,431.40
-2,173.40
12/31/2020 - 6/20/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
6535.TWO Lumosa Therapeutics Co., Ltd.
263.50
-0.57%
4162.TWO PharmaEngine, Inc.
95.10
+2.15%
6589.TWO EirGenix Inc.
79.80
+1.01%
6712.TWO Ever Supreme Bio Technology Co., Ltd
175.50
-0.28%
6733.TWO BioGend Therapeutics Co., Ltd.
33.00
0.00%
4174.TWO OBI Pharma, Inc.
56.90
+1.25%
4167.TWO Savior Lifetec Corporation
19.75
-0.25%
3176.TWO Medigen Biotechnology Corp.
32.60
-1.21%
4147.TWO TaiMed Biologics Inc.
86.50
+0.35%
4168.TWO GlycoNex Incorporation
24.00
0.00%